Pharma Marking – Treatment Of Ovarian Cancer Looks Promising

MLT CreativeIndustries

Author: MLT Creative

Recently it was announced that CA4P, an ovarian cancer treatment investigation drug of Mateon Therapeutics, was showing favorable results when combined with Roche’s Avastin, (bevacizumab) in a focus study assessing the effectiveness of the combination drugs along with chosen chemotherapy treatment in treating patients with prOC or platinum resistant ovarian cancer. According to reports, CA4P (combretastatin A-4 phosphate) targets the …

Pharma Coding – Bristol-Myers Squibb Acquires IFM Therapeutics

MLT CreativeIndustry News

Author: MLT Creative

Recent news reports reveal that BMS and IFM Therapeutics have signed an agreement in which Bristol-Myers Squibb will acquire full rights to IFM’s NLRP3 and STING agonist programs in an effort to target innate immunity pathways that could potentially assist the body’s natural defenses in recognizing tumors and attacking them, expanding and complementing Bristol-Myers Squibb’s immuno-oncology portfolio. Reports claim BMS …

Pharma Coders – Naloxone Prescription Reform In Maine

MLT CreativeNews

Author: MLT Creative

Narcan, the brand name of naloxone, a drug used to reverse overdose in those who have taken opioids, will become available in Maine without a prescription from a doctor, as one keyword added to the bill last month would make it possible for pharmacists to prescribe the medicine. News reports state Assistant Attorney General, Andrew Black, said in written testimony …

FDA’s Decision To Delay Serialization Regulations Indicates Stragglers

MLT CreativeNews

Author: MLT Creative

Up until recently, the deadline for pharmaceutical companies and contract manufacturers to meet serialization regulations regarding assignment of product identifiers to packages was November 26 of this year. Now the FDA has made the decision to push this date back to November of 2018, a one year delay. Many industry representatives feel this delay indicates that manufacturers in both the …

Pharma Marking – FDA Approves Vosevi For Hepatitis C

MLT CreativeIndustries

Author: MLT Creative

The FDA has recently given approval to Gilead Sciences for the use of the company’s Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets to re-treat adults who suffer from chronic hepatitis C virus infection, or HCV. According to reports, the single-tablet regimen is effective in most patients; two studies supported the claim that about 96% of patients involved in …